Memo Therapeutics acquired by Ipsen in deal valued up to €700 million
LONDON: Schroders Capital Global Innovation Trust plc announced that its portfolio company Memo Therapeutics AG has signed a definitive agreement for Ipsen to acquire its potravitug program, marking the fifth exit for the trust’s life sciences investments since 2019. The transaction focuses on…